Individualized risk assessment for use of hormone therapy in people with sickle cell disease
Authors:
- Maureen K. BaldwinMBMaureen K. Baldwin
- Bethany Samuelson BannowBBBethany Samuelson Bannow
- Rachel P. RosovskyRRRachel P. Rosovsky
- Nancy SokkaryNSNancy Sokkary
- Lakshmi V. SrivathsLSLakshmi V. Srivaths
Open Access
- 15 December 2023
- journal article
- letter
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 8 (1)
Abstract
No abstract availableThis publication has 3 references indexed in Scilit:
- Progestin-only contraception is first line for sickle cell disease: a comment on “Hormonal therapies in females with blood disorders: thrombophilia, thrombosis, hemoglobinopathies, and anemias.”Research and Practice in Thrombosis and Haemostasis, 2023
- Prevalence and outcomes of pulmonary embolism with sickle cell disease: Analysis of the Nationwide Inpatient Sample, 2016–2020European Journal of Haematology, 2023
- Prevalence and Risk Factors for Pulmonary Embolism in Pediatric Sickle Cell Disease: A National Administrative Database StudyPediatric Hematology and Oncology, 2023